Company’s Previous Response Left Unanswered Questions About EpiPen Pricing Impact on Consumers, Taxpayers, and Insurance Premiums
Washington, DC -(ENEWSPF)–November 1, 2016. In a 13-page letter sent today to the CEO of pharmaceutical company Mylan, 17 senators requested additional information about the company’s recent EpiPen Auto-Injector (EpiPen) price increases and how Mylan’s pricing strategy affects consumers, taxpayers, and insurance premiums. The letter follows a previous requestfor information made in August about the EpiPen price hike.…
